FY2029 Earnings Forecast for MBRX Issued By Roth Capital

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Research analysts at Roth Capital issued their FY2029 earnings per share (EPS) estimates for shares of Moleculin Biotech in a report issued on Thursday, January 9th. Roth Capital analyst J. Aschoff expects that the company will earn $2.81 per share for the year. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

A number of other research analysts have also recently weighed in on MBRX. Maxim Group lowered their target price on shares of Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th. StockNews.com initiated coverage on Moleculin Biotech in a research report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Moleculin Biotech Stock Up 0.6 %

Shares of NASDAQ:MBRX opened at $1.65 on Monday. Moleculin Biotech has a 1-year low of $1.50 and a 1-year high of $11.10. The firm’s 50 day simple moving average is $2.25 and its two-hundred day simple moving average is $2.61.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC raised its stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the period. Armistice Capital LLC owned 6.75% of Moleculin Biotech worth $549,000 as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.